BKM120+Abiraterone Acetate for Metastatic CRPC

This study has been terminated.
(Due to continued slow accrual the supllier of BKM120 requested that we cease further enrollment.)
Sponsor:
Information provided by (Responsible Party):
Glenn Bubley, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01741753
First received: December 3, 2012
Last updated: January 25, 2016
Last verified: January 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: September 2017
  Estimated Primary Completion Date: November 2016 (Final data collection date for primary outcome measure)